Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345933 | 1.00 | CA2 (0.40) | CA2CA1MGAMGAASI | |
| SCHEMBL9127986 | 0.94 | CA2 (0.40) | CA2CA1MGAMGAASI | |
| SCHEMBL9126513 | 0.94 | CA2 (0.40) | CA2CA1MGAMGAASI | |
| SCHEMBL4105283 | 0.88 | CA2 (0.41) | CA2CA1MGAMGAASI | |
| SCHEMBL1300747 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI | |
| SCHEMBL11628264 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI | |
| SCHEMBL12103336 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI | |
| SCHEMBL7150853 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI | |
| SCHEMBL1738813 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI | |
| SCHEMBL13482823 | 0.84 | CA2 (0.38) | CA2CA1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | NOVARTIS AG | 2008-11-06 | — | — | US | disclosed |
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | NOVARTIS AG | 2008-11-06 | — | — | US | disclosed |
| US-7378410-B2 | Substituted lactams and their use as anti-cancer agents | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-7378410-B2 | Substituted lactams and their use as anti-cancer agents | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | TOP1, TOP2A, MYC | CA2 4540/4885CA1 3807/4885MGAM 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.